Mini-Percutaneous Nephrolithotomy Yields Higher Stone-Free Rate

FRIDAY, May 26, 2023 (HealthDay News) -- Mini-percutaneous nephrolithotomy (mPCNL) is more likely to result in stone-free than flexible ureteroscopy for adults with renal stones of 1 to 2 cm in size, according to a study published in the June issue of The Journal of Urology.
Rahul Dutta, M.D., from Wake Forest University in Winston Salem, North Carolina, and colleagues evaluated the outcomes of ureteroscopy (50 patients) versus prone mPCNL (51 patients) for adults with 1-cm to 2-cm renal stones.
The researchers found that the stone-free rate was higher in the mPCNL group (76 versus 46 percent) when using a 2-mm cutoff. In the ureteroscopy group, the residual stone burden was significantly higher (3.6 versus 1.4 mm), whereas fluoroscopy time was significantly higher in the mPCNL group (273 versus 49 seconds). There were no significant differences noted in postoperative complications within 30 days, necessity of a secondary procedure within 30 days, or preoperative to postoperative creatinine change. Surgical time was also similar between the groups, but average length of stay was significantly higher in the mPCNL group. For mPCNL procedures, both net revenue and direct costs were higher, though they offset each other with a nonsignificant operating margin.
"In patients with intermediate-sized kidney stones, mini-PCNL may offer a more effective procedure, with similar safety and cost impact," senior author Jorge Gutierrez-Aceves, M.D., of the Cleveland Clinic, said in a statement.
Related Posts
Screening Could Help Identify Familial Hypercholesterolemia
WEDNESDAY, May 18, 2022 (HealthDay News) -- Screening for familial...
Many Stroke Survivors Have Ongoing Irregular Heart Rhythms
THURSDAY, Feb. 9, 2023 (HealthDay News) -- About 20% of people who survive...
Meat-Heavy Diets Might Have Link to MS
TUESDAY, Feb. 1, 2022 (HealthDay News) -- If you eat a lot of meat, you may be...
Patient-Rated Tardive Dyskinesia Linked to QoL, Social Functioning
WEDNESDAY, April 19, 2023 (HealthDay News) -- For antipsychotic-treated...